RANCHO CORDOVA, Calif., Oct. 24 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. today announced that it has engaged New York-based healthcare communications firm, Lazar Partners, Ltd., to develop and implement a comprehensive financial communications program. Lazar Partners will focus on increasing visibility for ThermoGenesis and its portfolio of products including the BioArchive(R) System and AutoXpress(TM) System that enable the precision processing and storage of stem cells and the CryoSeal(R) FS System and TPD(TM) platform products which make surgical adhesives using a patient’s own blood.
“ThermoGenesis is well-positioned to take advantage of perhaps the most important advance in healthcare -- the development of ‘personalized medicines’ for the treatment of debilitating and lethal diseases. Building visibility will enable our stakeholders to understand the vital role that our technologies play in advancing patient care and is fundamental to taking our company to the next level in its development,” said Philip H. Coelho, Chief Executive Officer, ThermoGenesis. “Lazar Partners has the experience in communicating breakthrough technologies and creating awareness that will enable us to expand understanding of our company among our target audiences.”
“We are very proud to be working with ThermoGenesis to broaden awareness of their significant contributions in realizing the potential of personalized cellular medicines. ThermoGenesis’ BioArchive and AutoXpress Systems enable the cGMP manufacturing of specific cell populations that are targeted for each patient’s best care. Similarly, the CryoSeal FS System is being used by hospital and surgical centers to provide clinically effective wound healing products from the patient’s own safe blood.” said Fern Lazar, President of Lazar Partners, Ltd.
ABOUT THERMOGENESIS
ThermoGenesis Corp. is a leader in enabling technologies for cell therapeutics and surgical hemostasis. The Company’s technology platforms lead the world in their ability to produce biological products from single units of blood. Umbilical cord blood banks are utilizing the Company’s BioArchive System as a critical enabling technology for cryogenic archiving of stem cells for transplant, while its CryoSeal FS System is used to prepare hemostatic and adhesive surgical sealants from the patient’s blood in about an hour. The CryoSeal System is currently not available in the United States. ThermoGenesis Corp. has been a leading supplier of state-of-the-art Ultra- Rapid Blood Plasma Freezers and Thawers to hospitals and blood banks since 1992. For more information about ThermoGenesis Corp, visit their website at http://www.thermogenesis.com .
The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company’s control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission.
ThermoGenesis Corp.
CONTACT: Mina Robertson of ThermoGenesis Corp., +1-916-858-5100, ormrobertson@thermogenesis.com; or Fern Lazar of Lazar Partners, Ltd.,+1-212-867-1762, or flazar@lazarpartners.com
Web site: http://www.thermogenesis.com/
